Sumatriptan, a serotonin-1 receptor agonist specially developed for migraine, became available as a licensed product for adults more than 20 years ago. Since then, numerous controlled studies with sumatriptan have been carried out and it is widely used in adults. However, the story has not been as successful in children and adolescents as in adults. Of the few studies performed, most have shown...

normal 0 false false false en-us x-none ar-sa background: there are different options to manage benign headache in the emergency department. the costs, side effects, and efficacies of the drugs used are significantly different. the aim of this study was to compare intravenous (iv) metoclopramide with subcutaneous (sc) sumatriptan in treatment of migraine headache. material and methods: in a ran...

benefit offered by sumatriptan therapy? Cephalalgia 1995; 15(suppl 14):263 12 Fowler PA, Lacey LF, Thomas M, Keene ON, Tanner RJN, Baber NS. The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan. Eur Neurol 1991; 31:291-4. 13 Blau JN. Sumatriptan and the recurrence of migraine. Lancet 1992;340: 1110. 14 Mathew NT. Drug-induced headache. Neurol Clin 1990; 8:903-12. 15 Mathew ...

Objectives: The objective was to evaluate the seizure provoking effect of sumatriptan, and its abolition with fluoxetine in the pentylenetetrazolinduced seizures in rats. Methods: 100 Sprague-Dawley rats of either sex were randomized into 10 groups with each group consisting 10 rats. The first group was taken as a control group which received distilled water. The second group and the third grou...

Lithium is a drug used for the treatment of bipolar disorder. It has several mechanisms of action, and recently it is shown that lithium can antagonize the 5-HT1B/1D serotonin receptors. Sumatriptan is a 5-HT1B/1D receptor agonist used for the treatment of cluster headaches and migraine which might cause memory impairment as a potential side effect. In this study, effects of lithium on sumatrip...

igraine causes substantial patient suffering and high costs to managed care organizations and employers. Triptans (5-HT1B/1D receptor agonists) are effective and relatively safe for the acute treatment of migraine. Initial treatment with a triptan is recommended when the migraine is judged moderate to severe or in migraine of any severity when nonsteroidal anti-inflammatory drugs and combinatio...

Sumatriptan succinate, a 5-HT1D receptor agonist, constricts human cranial arteries. Two parallel-group trials for treatment of acute migraines were conducted in the United States. Adult patients were randomized and given either 6 mg of sumatriptan succinate subcutaneously (n = 734) or placebo (n = 370). At 1 hour, sumatriptan was significantly more effective than placebo in reducing moderate o...

BACKGROUND Pharmacological studies of the enteric nervous system have shown the presence of several subtypes of 5-hydroxytryptamine (5HT) receptor, which might be involved in control of the migrating motor complex. AIMS To study the effect of sumatriptan, an agonist of enteric neuronal 5HT1p receptors, on interdigestive motility in man. SUBJECTS AND METHODS In 12 healthy subjects, interdige...

Sumatriptan, a novel selective 5-hydroxytryptamine1d (5-HT1d) receptor agonist, which is highly effective in the acute treatment of migraine attacks, blocks dural neurogenic plasma extravasation and constricts cranial blood vessels in animal experiments. We measured intra- and extracranial blood flow velocities (BFV) with a transcranial Doppler device in 67 patients during a spontaneous migrain...

OBJECTIVE To compare the efficacy of oral eletriptan, 40 mg and 80 mg, and oral sumatriptan, 50 mg and 100 mg, in the acute treatment of migraine. METHODS Patients with a history of migraine (n = 1,008) were randomly assigned to receive placebo, 40 mg of eletriptan, 80 mg of eletriptan, 50 mg of sumatriptan, or 100 mg of sumatriptan to treat up to three attacks. Early headache response (at 1 ...